{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:12:24Z","timestamp":1778109144150,"version":"3.51.4"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jsbmb.2026.107019","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:38:45Z","timestamp":1775633925000},"page":"107019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New insights into prostate cancer progression: A focus on vitamin D signaling"],"prefix":"10.1016","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4585-7971","authenticated-orcid":false,"given":"Vanessa","family":"Friedrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Laverny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2026.107019_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.jsbmb.2026.107019_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2026.107019_bib3","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1101\/gad.819500","article-title":"Molecular genetics of prostate cancer","volume":"14","author":"Abate-Shen","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.jsbmb.2026.107019_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fruro.2024.1487873","article-title":"Intermediate risk prostate tumors contain lethal subtypes","volume":"4","author":"Harryman","year":"2025","journal-title":"Front. Urol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/JU.0000000000001011","article-title":"Rare histological variants of prostate adenocarcinoma: a national cancer database analysis","volume":"204","author":"Bronkema","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jsbmb.2026.107019_bib7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2026.107019_bib8","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.3390\/cancers15204945","article-title":"De Novo metastatic prostate cancer: are we moving toward a personalized treatment?","volume":"15","author":"Piombino","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jsbmb.2026.107019_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390166","article-title":"Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment","author":"Hamid","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.jsbmb.2026.107019_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5489\/cuaj.4146","article-title":"One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading","volume":"10","author":"Srigley","year":"2016","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.jsbmb.2026.107019_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2559.2011.04025.x","article-title":"Staging of prostate cancer","volume":"60","author":"Cheng","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.jsbmb.2026.107019_bib13","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma","volume":"44","author":"Van Leenders","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000002430","article-title":"Members of the ISUP GU Cancer Precursor Consensus Panel, International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate","author":"Iczkowski","year":"2025","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib15","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2024.0019","article-title":"Side effects of prostate cancer therapies and potential management","volume":"11","author":"Xiao","year":"2024","journal-title":"J. Biol. Methods"},{"key":"10.1016\/j.jsbmb.2026.107019_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2026.107019_bib21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2026.107019_bib24","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.07.042","article-title":"Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers","author":"Grist","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jsbmb.2026.107019_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.euo.2025.09.009","article-title":"Prognostic implications of very high decipher scores in prostate cancer: towards a refined genomic risk classification","volume":"9","author":"Sharma","year":"2026","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/his.70036","article-title":"Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence","volume":"88","author":"Greenland","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.jsbmb.2026.107019_bib28","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib30","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib33","article-title":"Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer","volume":"3","author":"Siddiqui","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib34","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib36","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2024.42.16_suppl.2536","article-title":"Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer","volume":"42","author":"Heitmann","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib37","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e17161","article-title":"Hangzhou DAC Biotechnology Co. Ltd., The anti-STEAP1\/PSMA ADC, DXC008: assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib39","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1677\/erc.1.00795","article-title":"Primary cell cultures as models of prostate cancer development","volume":"12","author":"Peehl","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107019_bib41","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/cancers12092651","article-title":"Cellular and molecular progression of prostate cancer: models for basic and preclinical research","volume":"12","author":"Saranyutanon","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jsbmb.2026.107019_bib42","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1111\/bph.16492","article-title":"A vitamin D-based strategy overcomes chemoresistance in prostate cancer","volume":"181","author":"Len-Tayon","year":"2024","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.jsbmb.2026.107019_bib43","author":"Ahmed","year":"2024","journal-title":"How Clin. Relev. are Prostate Cancer Cell lines? A Compr. Character multiomics Comp."},{"key":"10.1016\/j.jsbmb.2026.107019_bib44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.yexcr.2010.10.012","article-title":"Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer","volume":"317","author":"Chauchereau","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib45","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.6.2.333","article-title":"Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells - differentiation pattern of nontumorigenic cell-lines","author":"Berthon","year":"1995","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116352","article-title":"Single-cell analysis uncovers preserved prostate cancer lineages and universally altered pathways in Matrigel-free patient-derived organoids","volume":"44","author":"Dolgos","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.jsbmb.2026.107019_bib47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13046-025-03540-2","article-title":"Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response","volume":"44","author":"Kang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib48","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","article-title":"Patient-derived xenografts and organoids model therapy response in prostate cancer","volume":"12","author":"Karkampouna","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsbmb.2026.107019_bib49","article-title":"Microfluidic-based human prostate-cancer-on-chip","volume":"12","author":"Jiang","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/acs.analchem.8b05293","article-title":"Recent advances in body-on-a-chip systems","volume":"91","author":"Sung","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jsbmb.2026.107019_bib51","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1039\/D5LC00503E","article-title":"In situ formation and culture of cell spheroids in a low-binding 3D-printed biochip","volume":"25","author":"Martins","year":"2025","journal-title":"Lab. Chip"},{"key":"10.1016\/j.jsbmb.2026.107019_bib52","author":"Parmentier","year":"2026","journal-title":"A Modul. Patient-Deriv. Organo xenograft Platf. Reveals Mol. Clin. trajectories Prostate Cancer Progress."},{"key":"10.1016\/j.jsbmb.2026.107019_bib53","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/pros.23701","article-title":"Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models","volume":"78","author":"Navone","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2026.107019_bib54","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/life15111719","article-title":"A feasibility study of co-established patient-derived subcutaneous xenograft and organotypic slice cultures in hormone-naive primary prostate cancer preclinical modeling: a single-institution experience","volume":"15","author":"Pecci","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.jsbmb.2026.107019_bib55","article-title":"Patient-derived xenograft models: current status, challenges, and innovations in cancer research","volume":"12","author":"Liu","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.jsbmb.2026.107019_bib56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41585-022-00706-x","article-title":"The future of patient-derived xenografts in prostate cancer research","volume":"20","author":"Lawrence","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.molonc.2013.02.005","article-title":"Genetically engineered mouse models of prostate cancer","volume":"7","author":"Parisotto","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib58","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","article-title":"Prostate cancer in a transgenic mouse","volume":"92","author":"Greenberg","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107019_bib59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10555-012-9409-1","article-title":"Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic","volume":"32","author":"Irshad","year":"2013","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.jsbmb.2026.107019_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10555-013-9487-8","article-title":"Mouse models of prostate cancer: picking the best model for the question","volume":"33","author":"Grabowska","year":"2014","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.jsbmb.2026.107019_bib61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.4924","article-title":"A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours","volume":"243","author":"Sackmann Sala","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib62","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.3390\/cancers14153775","article-title":"Transcriptomic signature and growth factor regulation of castration-tolerant prostate luminal progenitor cells","volume":"14","author":"Baures","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jsbmb.2026.107019_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s44321-026-00375-y","article-title":"Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy","author":"Baur\u00e8s","year":"2026","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib64","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1073\/pnas.0712021105","article-title":"Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma","volume":"105","author":"Ratnacaram","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107019_bib65","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/dvg.20386","article-title":"Temporally controlled prostate epithelium-specific gene alterations","volume":"46","author":"Luchman","year":"2008","journal-title":"Genesis"},{"key":"10.1016\/j.jsbmb.2026.107019_bib66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/9780470942390.mo100128","article-title":"Generation of spatio-temporally controlled targeted somatic mutations in the mouse","volume":"1","author":"Metzger","year":"2011","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib67","article-title":"Senescence controls prostatic neoplasia driven by Pten loss","volume":"6","author":"Parisotto","year":"2019","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2295","article-title":"Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression","volume":"8","author":"Abu El Maaty","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jsbmb.2026.107019_bib69","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217209","article-title":"Hypoxia-inducible factor 1A inhibition overcomes castration resistance of prostate tumors","volume":"15","author":"Terzic","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jsbmb.2026.107019_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers17040645","article-title":"TP53 deficiency in the natural history of prostate cancer","volume":"17","author":"Ofner","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.jsbmb.2026.107019_bib71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41419-025-07361-1","article-title":"p53-loss induced prostatic epithelial cell plasticity and invasion is driven by a crosstalk with the tumor microenvironment","volume":"16","author":"Yanushko","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jsbmb.2026.107019_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-026-08590-8","article-title":"HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer","author":"Yanushko","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jsbmb.2026.107019_bib73","article-title":"History of the discovery of vitamin D and its active metabolites","volume":"3","author":"DeLuca","year":"2014","journal-title":"Bone Rep."},{"key":"10.1016\/j.jsbmb.2026.107019_bib74","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1073\/pnas.76.11.5485","article-title":"Purification of chicken intestinal receptor for 1,25-dihydroxyvitamin D","volume":"76","author":"Pike","year":"1979","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107019_bib75","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.3029866","article-title":"Molecular cloning of complementary DNA encoding the avian receptor for vitamin D","volume":"235","author":"McDonnell","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jsbmb.2026.107019_bib76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1097-2765(00)80413-X","article-title":"The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand","volume":"5","author":"Rochel","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jsbmb.2026.107019_bib77","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.celrep.2014.12.045","article-title":"A vitamin D receptor selectively activated by gemini analogs reveals ligand dependent and independent effects","volume":"10","author":"Huet","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.jsbmb.2026.107019_bib78","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1073\/pnas.93.15.7861","article-title":"1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis","volume":"93","author":"Cantorna","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107019_bib79","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1158\/0008-5472.CAN-05-1435","article-title":"Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells","volume":"65","author":"Moreno","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib80","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-05-3796","article-title":"Inhibition of p38 by Vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D","volume":"66","author":"Nonn","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.imlet.2010.03.006","article-title":"Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease","volume":"131","author":"Laverny","year":"2010","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jsbmb.2026.107019_bib82","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/biology13050346","article-title":"1,25-Dihydroxyvitamin D3 suppresses prognostic survival biomarkers associated with cell cycle and actin organization in a non-malignant african american prostate cell line","volume":"13","author":"Johnson","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.jsbmb.2026.107019_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117497","article-title":"Effects of Vitamin D on tumor cell proliferation and migration, tumor initiation and anti-tumor immune response in head and neck squamous cell carcinomas","volume":"180","author":"Brust","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.jsbmb.2026.107019_bib84","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.adh7954","article-title":"Vitamin D regulates microbiome-dependent cancer immunity","volume":"384","author":"Giampazolias","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jsbmb.2026.107019_bib85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0140-6736(89)91204-X","article-title":"Possible role for vitamin d in controlling breast cancer cell proliferation","volume":"333","author":"Colston","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2026.107019_bib86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bonr.2018.06.002","article-title":"Calcitriol and cancer therapy: a missed opportunity","volume":"9","author":"Trump","year":"2018","journal-title":"Bone Rep."},{"key":"10.1016\/j.jsbmb.2026.107019_bib87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/aja.aja_14_18","article-title":"Vitamin D in prostate cancer","volume":"20","author":"Trump","year":"2018","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.jsbmb.2026.107019_bib88","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semcancer.2020.05.018","article-title":"An update on vitamin D signaling and cancer","volume":"79","author":"Carlberg","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib89","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.3390\/ijms252010914","article-title":"Anticancer activity of vitamin D, lumisterol and selected derivatives against human malignant melanoma cell lines","volume":"25","author":"Dom\u017calski","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2026.107019_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2025.112603","article-title":"Inhibition of the RIPK4 enhances suppression of human melanoma growth through vitamin D signaling","volume":"607","author":"Olajossy","year":"2025","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib91","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-13-3085","article-title":"Vitamin D deficiency predicts prostate biopsy outcomes","volume":"20","author":"Murphy","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib92","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i6.108113","article-title":"Vitamin D deficiency in prostate cancer: prevalence in a sun-rich climate and influence of androgen deprivation therapy","volume":"16","author":"Hasan","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib93","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1940-6207.CAPR-18-0401","article-title":"Vitamin D signaling suppresses early prostate carcinogenesis in TgAPT121 Mice","volume":"12","author":"Fleet","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109177","article-title":"Vitamin D deficiency aggravates growth and metastasis of prostate cancer through promoting EMT in two \u03b2-catenin-related mechanisms","volume":"111","author":"Zhang","year":"2023","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jsbmb.2026.107019_bib95","doi-asserted-by":"crossref","unstructured":"K. Len-Tayon, J. Gantzer, C. Dariane, O. Fogel, V. Friedrich, D. Rovito, V. Lindner, V. Gilbart, D. Yanushko, S. Henri, D. Metzger, G. Laverny,\u00a0Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination,\u00a0Embo Mol Med. In press, doi:10.1038\/s44321-026-00417-5.","DOI":"10.1038\/s44321-026-00417-5"},{"key":"10.1016\/j.jsbmb.2026.107019_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105522","article-title":"Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials","volume":"198","author":"Manson","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib97","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1210\/endo.139.3.5770","article-title":"Antiproliferative effect of 1\u03b1,25-Dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation","volume":"139","author":"Zhuang","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2026.107019_bib98","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/pros.21201","article-title":"1,25-dihydroxyvitamin D3 and PI3K\/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells","volume":"70","author":"Axanova","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2026.107019_bib99","first-page":"667","article-title":"Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer","volume":"1","author":"Guzey","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jsbmb.2026.107019_bib100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/pros.21226","article-title":"1\u03b1,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest","volume":"71","author":"Washington","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2026.107019_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105828","article-title":"1\u03b1,25-Dihydroxyvitamin D3 synergistically enhances anticancer effects of ginsenoside Rh2 in human prostate cancer cells","volume":"209","author":"Ben-Eltriki","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib102","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ajpath.2010.10.036","article-title":"Suppression of prostate cancer cell rolling and adhesion to endothelium by 1\u03b1,25-dihydroxyvitamin D3","volume":"178","author":"Hsu","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/2767-9764.CRC-22-0389","article-title":"African American prostate cancer displays quantitatively distinct vitamin D receptor cistrome-transcriptome relationships regulated by BAZ1A","volume":"3","author":"Siddappa","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.jsbmb.2026.107019_bib104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/0008-5472.CAN-16-0687","article-title":"Vitamin D3 prevents calcium-induced progression of early-stage prostate tumors by counteracting TRPC6 and calcium sensing receptor upregulation","volume":"77","author":"Bernichtein","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib105","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1158\/1940-6207.CAPR-11-0035","article-title":"Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate","volume":"4","author":"Kovalenko","year":"2011","journal-title":"Cancer Prev. Res. (Phila. Pa. )"},{"key":"10.1016\/j.jsbmb.2026.107019_bib106","first-page":"727","article-title":"Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model","volume":"32","author":"Ray","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jsbmb.2026.107019_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089555","article-title":"Early growth inhibition is followed by increased metastatic disease with vitamin D (Calcitriol) treatment in the TRAMP model of prostate cancer","volume":"9","author":"Ajibade","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2026.107019_bib108","first-page":"195","article-title":"Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer","volume":"1","author":"Osborn","year":"1995","journal-title":"Urol. Oncol. Semin. Orig. Invest."},{"key":"10.1016\/j.jsbmb.2026.107019_bib109","first-page":"2647","article-title":"Calcitriol in the treatment of prostate cancer","volume":"26","author":"Beer","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2017.02.015","article-title":"Vitamin D analogues: potential use in cancer treatment","volume":"112","author":"Duffy","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg5982","article-title":"Single-cell analyses unravel cell type\u2013specific responses to a vitamin D analog in prostatic precancerous lesions","volume":"7","author":"Abu El Maaty","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jsbmb.2026.107019_bib112","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1200\/jco.2011.29.15_suppl.4605","article-title":"Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC)","volume":"29","author":"Medioni","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib113","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1158\/1078-0432.CCR-13-3247","article-title":"Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients","volume":"20","author":"Medioni","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107019_bib114","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107019_bib115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.otohns.2005.05.658","article-title":"Combination docetaxel plus vitamin D3 as an immune therapy in animals bearing squamous cell carcinomas","volume":"133","author":"Young","year":"2005","journal-title":"Otolaryngol. Neck Surg."},{"key":"10.1016\/j.jsbmb.2026.107019_bib116","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.21873\/anticanres.12823","article-title":"Effect of vitamin D on paclitaxel efficacy in triple-negative breast cancer cell lines","volume":"38","author":"Wilhelm","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jsbmb.2026.107019_bib117","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026000853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026000853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:25:59Z","timestamp":1778106359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076026000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":117,"alternative-id":["S0960076026000853"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107019","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into prostate cancer progression: A focus on vitamin D signaling","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107019"}}